Dura forecasts Ceclor CD, Keftab sales of $100 mil. in 2000 following acquisition from Lilly.
Executive Summary
DURA PREDICTS CECLOR CD, KEFTAB ANTIBIOTIC SALES OF $100 MIL. in the year 2000, the company said Aug. 22 announcing the acquisition of U.S. marketing rights to the two antibiotics from Lilly for approximately $100 mil. Under the marketing agreement, Lilly will manufacture Keftab and Ceclor CD, which gained FDA approval June 24. Dura expects to launch the twice-a-day Ceclor (cefaclor) this autumn and plans to promote Keftab (cephalexin) to physicians immediately. Keftab's current annual sales are about $15 mil., Dura said.